<DOC>
	<DOCNO>NCT01220726</DOCNO>
	<brief_summary>This prospective , randomize , double-blind study compare intravesical injection BOTOX placebo . Study subject randomize ( 1:1 ratio ) one follow treatment group : Group 1 n=20 BOTOX® 200U Group 2 n=20 Placebo BOTOX® ( saline ) At Visit 2 ( Treatment , Day 0 ) , subject receive one injection cycle BOTOX ( 200U ) placebo ( saline ) . The study duration approximately 284 day consist Screening Visit ( Day -7 -14 ) , Treatment/Randomization Visit ( Visit 2 , Day 0 ) , Follow-up Visits 7 , 30 , 90 , 180 , 270 Days . Telephone Follow-ups make 3 day follow injection cycle . Subjects demonstrate insufficient response treatment may receive open-label injection cycle BOTOX ( 200U ) Day 90 . Subjects receive injection re-commence Follow-up Visits follow additional 270 day .</brief_summary>
	<brief_title>Botox Treatment Overactive Bladder Secondary Benign Prostatic Obstruction</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>1 . Male outpatient race , 40 90 year age . 2 . Clinical sign symptom frequency ( &gt; =8 micturitions/day ) urgency ( &gt; =2 episodes/day ) . 3 . Urodynamic history consistent OAB develop conjunction BPO persist least 3 month post TURP PVP , RRP obstruction relieve procedure . 4 . OAB inadequately control anticholinergic medication , per Investigator opinion . 5 . Qmax &gt; 12mL/s voided volume &gt; 125mL . 6 . IPSS &gt; 12 , IPSS QoL &gt; 3 study Visit 1 . 7 . Willing use clean intermittent catheterization ( CIC ) empty bladder willing indwelling catheter , necessary follow study treatment . 8 . Able understand requirement study , include complete questionnaire sign Informed Consent/HIPAA . 1 . Known history interstitial cystitis , uninvestigated hematuria , bladder outlet obstruction due vesical neck contracture , mullerian duct cyst , urethral obstruction due stricture/valves/sclerosis urethral tumor , radiation cystitis , genitourinary tuberculosis , bladder calculus , detrusorsphincter dyssynergia . 2 . Known history clinically significant cardiovascular disease , cerebrovascular disease , arrhythmia . 3 . History spinal cord injury multiple sclerosis , neurological disease may contribute OAB . 4 . Known history hydronephrosis . 5 . Current indwelling catheter , removal chronic catheter &lt; 1 month prior study entry . 6 . Noncompliance washout period prohibit medications/therapies ( Supplement I ) . 7 . Evidence Urinary Tract Infection accord local standard care . 8 . Serum PSA &gt; 10ng/mL . 9 . 24 hour total volume void &gt; 3000 mL urine . [ As determined completion patient bladder diary screening period ] 10 . Medical condition may increase risk exposure botulinum toxin include diagnose Myasthenia Gravis , EatonLambert Syndrome , Amyotrophic Lateral Sclerosis disease might interfere neuromuscular function . 11 . Allergy sensitivity component BOTOX® ( Section 5.2 ) . 12 . Known uncontrolled systemic disease . 13 . Evidence recent alcohol/drug abuse . 14 . Subjects , opinion Investigator , significant condition put significant risk , may confound study result , interfere study participation . 15 . History poor cooperation , noncompliance medical treatment , unreliability .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>OAB</keyword>
</DOC>